ARID1A alterations function as a biomarker for longer progression-free survival after anti-PD-1/PD-L1 immunotherapy

BackgroundSeveral cancer types harbor alterations in the gene encoding AT-Rich Interactive Domain-containing protein 1A (ARID1A), but there are no approved therapies to address these alterations. Recent studies have shown that ARID1A deficiency compromises mismatch repair proteins. Herein, we analyz...

Full description

Saved in:
Bibliographic Details
Published in:Journal for immunotherapy of cancer 2020-02, Vol.8 (1), p.e000438
Main Authors: Okamura, Ryosuke, Kato, Shumei, Lee, Suzanna, Jimenez, Rebecca E, Sicklick, Jason K, Kurzrock, Razelle
Format: Article
Language:English
Subjects:
Adult
Aged
Aged, 80 and over
Apoptosis
B7-H1 Antigen - metabolism
biomarker
Biomarkers, Tumor - immunology
Bladder
Breast cancer
Cancer
Cholangiocarcinoma
DNA-Binding Proteins - metabolism
Endometrial cancer
Esophagus
FDA approval
Female
Genes
Humans
immune checkpoint inhibitor
Immunotherapy
Immunotherapy - methods
Immunotherapy biomarkers
Kinases
Laboratories
Ligands
Liver cancer
Lung cancer
Male
Melanoma
microsatellite instability
Middle Aged
Multivariate analysis
Mutation
Ovarian cancer
Patients
PD-L1
Principal components analysis
Progression-Free Survival
Proteins
Short Report
Transcription Factors - metabolism
tumor mutation burden
Tumors
Young Adult
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:BackgroundSeveral cancer types harbor alterations in the gene encoding AT-Rich Interactive Domain-containing protein 1A (ARID1A), but there are no approved therapies to address these alterations. Recent studies have shown that ARID1A deficiency compromises mismatch repair proteins. Herein, we analyzed 3403 patients who had tumor tissue next-generation sequencing.FindingsAmong nine cancer subtypes with >5% prevalence of ARID1A alterations, microsatellite instability-high as well as high tumor mutational burden was significantly more frequent in ARID1A-altered versus ARID1A wild-type tumors (20% vs 0.9%, p
ISSN:2051-1426
2051-1426
DOI:10.1136/jitc-2019-000438